Braden Michael Leonard
CIK 1373603 · last filed 2026-05-18
Braden Michael Leonard is a corporate insider who has filed 110 SEC Form 4 insider transactions across 16 companies since 2009. The most recent filing shows the insider exercised options on $1.6M of OM on May 18, 2026. Across all open-market trades the lifetime net is −$13.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $160.4M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$160.40M
16
110
-$13.51M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| OM | 10%+ Owner | 2,519,701 | $4.72 | $11.89M | $0 | 2 | 2026-05-18 |
| ACRS | 10%+ Owner | 13,950,000 | $5.33 | $74.35M | $4.23M | 8 | 2026-04-27 |
| Adverum Biotechnologies, Inc. (ADVM) Delisted | 10%+ Owner | 2,149,880 | $4.36 | $9.37M | $1.41M | 11 | 2025-12-05 |
| ASTC | 10%+ Owner | 0 | $6.41 | $0 | -$815.2K | 8 | 2025-10-07 |
| ANTX | 10%+ Owner | 3,017,432 | $4.70 | $14.18M | -$1.53M | 3 | 2025-06-16 |
| OKUR | 447,815 | $3.95 | $1.77M | $0 | 1 | 2024-10-09 | |
| OnKure Therapeutics, Inc. (RPHM) Delisted | 10%+ Owner | 447,817 | $18.20 | $8.15M | $1.73M | 5 | 2024-09-26 |
| Talis Biomedical Corp (TLIS) Delisted | 10%+ Owner | 217,951 | $2.84 | $619.0K | $56.1K | 1 | 2024-08-28 |
| Tectonic Therapeutic, Inc. (AVRO) Delisted | 10%+ Owner | 405,948 | $16.80 | $6.82M | $971.5K | 1 | 2024-05-15 |
| IMRA | 10%+ Owner | 499,444 | $14.49 | $7.24M | -$9.40M | 9 | 2023-01-05 |
| RVP | 10%+ Owner | 1,076,075 | $0.67 | $721.1K | -$2.08M | 7 | 2022-12-29 |
| Metacrine, Inc. (MTCR) Delisted | 10%+ Owner | 6,760,570 | $0.49 | $3.35M | $936.1K | 4 | 2022-12-21 |
| Satsuma Pharmaceuticals, Inc. (STSA) Delisted | 10%+ Owner | 6,590,000 | $1.10 | $7.25M | $4.50M | 2 | 2022-11-23 |
| Disc Medicine, Inc. (GMTX) Delisted | 10%+ Owner | 524,750 | $13.50 | $7.08M | $1.29M | 2 | 2022-10-27 |
| BBW | 1,423,043 | $35.31 | $50.25M | -$11.65M | 33 | 2017-10-02 | |
| ProPhase Labs, Inc. (PRPH) Delisted | 10%+ Owner | 62,732 | $0.11 | $6.9K | -$3.16M | 7 | 2017-10-02 |
Recent Filings
110 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-05-18 | OM | Exer (X) | +323,000 | $1.61M | EDGAR |
| 2026-05-12 | OM | Exer (X) | +294,500 | $1.47M | EDGAR |
| 2026-04-27 | ACRS | Sell (S) | −300,000 | -$1.36M | EDGAR |
| 2025-12-05 | Adverum Biotechnologies, Inc. (ADVM) Delisted | Sell (S) | −524,560 | -$2.20M | EDGAR |
| 2025-12-03 | Adverum Biotechnologies, Inc. (ADVM) Delisted | Sell (S) | −574,886 | -$2.41M | EDGAR |
| 2025-10-07 | ASTC | Sell (S) | −229,576 | -$1.63M | EDGAR |
| 2025-06-16 | ANTX | Sell (S) | −200,000 | -$218.0K | EDGAR |
| 2025-05-30 | ANTX | Sell (S) | −2,532,000 | -$2.87M | EDGAR |
| 2025-04-28 | Adverum Biotechnologies, Inc. (ADVM) Delisted | Buy (P) | +37,000 | $188.9K | EDGAR |
| 2025-04-28 | Adverum Biotechnologies, Inc. (ADVM) Delisted | Buy (P) | +37,000 | $188.9K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.